A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)(COMPLETED)

Official Title: “Designated Drug Use Investigation (12 Weeks) of Zetia 10mg Tablets - A 12-Week Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy”

This study is a non-interventional (observational) study in Japan to confirm the safety and efficacy of Zetia when administered alone or in combination with other lipid-lowering drugs in daily medical practice throughout a 12-week period. It is being conducted as a post-approval commitment, in accordance with the Ministry of Health, Labour and Welfare's guideline on Good Post-marketing Study Practice.

Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

The population will be selected from 2,000 institutions in Japan.

Intervention(s) in this Clinical Trial

• Drug: Ezetimibe
  • Ezetimibe, 10-mg tablets
• Drug: Ezetimibe + other lipid-lowering medication(s)
  • Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician

Arms, Groups and Cohorts in this Clinical Trial

• : Zetia monotherapy
  • Patients to be treated with Zetia alone (10-mg tablets,) for hypercholesterolemia
• : Zetia combination therapy
  • Patients to be treated with Zetia (10-mg tablets,) in combination with other lipid-lowering drugs for hypercholesterolemia

Primary Measures

• Incidence of adverse events
  • Time Frame: Adverse events will be monitored throughout the 12-week period. (Subjects who discontinue Zetia treatment during the 12-week period will be investigated up to the time of therapy discontinuation )
    Safety Issue?: Yes
• Change in LDL-C
  • Time Frame: LDL-C at start of 12 weeks will be compared to LDL-C at the end of the 12-week period.
    Safety Issue?: Yes

Inclusion Criteria:

• Subjects who have hypercholesterolemia, familial hypercholesterolemia, or homozygous sitosterolemia will be considered for this study.
• Zetia monotherapy patients must be treated with Zetia alone. Zetia combination therapy patients must be treated with Zetia in combination with other lipid-lowering drugs for hypercholesterolemia.

Exclusion Criteria:

• Patients with a history of hypersensitivity to any ingredient in Zetia
• Patients with serious hepatic function disorder should not be treated with Zetia in combination with an HMG-CoA reductase inhibitor.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Schering-Plough Industry

Information obtained from ClinicalTrials.gov on February 09, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00704444

Study ID Number: P05244

ClinicalTrials.gov Identifier: NCT00704444

Health Authority: Japan: Ministry of Health, Labor and Welfare